CliffBio
small molecule

DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameDAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE
Active ingredientDAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Strength5MG;1GM
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalApril 2026
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE patent cliff — loss of exclusivity — | CliffBio